过表达ERBB2的持续信号
中文名称
通路描述
ERBB2（HER2）的过表达，通常作为ERBB2基因扩增的后果，导致ERBB2同源二聚体的形成。在正常条件下，只有ERBB2异二聚体形成，因为ERBB2的表达水平较低。
ERBB2同源二聚化导致在没有生长因子的情况下激活ERBB2信号。ERBB2同源二聚体的信号主要激活RAS/RAF/MAPK信号级联，而PI3K/AKT信号并未受到显著影响（Pickl和Ries 2009）。
曲妥珠单抗（赫赛汀）是一种临床批准的重组抗体，用于治疗HER2过表达癌症，它优先结合ERBB2同源二聚体（Pickl和Ries 2009）。
对ERBB2信号进行准确的功能分析可能需要三维细胞培养而不是二维细胞培养（Pickl和Ries 2009）。
ERBB2同源二聚化导致在没有生长因子的情况下激活ERBB2信号。ERBB2同源二聚体的信号主要激活RAS/RAF/MAPK信号级联，而PI3K/AKT信号并未受到显著影响（Pickl和Ries 2009）。
曲妥珠单抗（赫赛汀）是一种临床批准的重组抗体，用于治疗HER2过表达癌症，它优先结合ERBB2同源二聚体（Pickl和Ries 2009）。
对ERBB2信号进行准确的功能分析可能需要三维细胞培养而不是二维细胞培养（Pickl和Ries 2009）。
英文描述
Constitutive Signaling by Overexpressed ERBB2 Overexpression of ERBB2 (HER2), usually as a consequence of ERBB2 gene amplification, results in formation of ERBB2 homodimers. Under normal conditions, only ERBB2 heterodimers form, as ERBB2 is expressed at low levels.
ERBB2 homodimerization leads to activation of ERBB2 signaling in the absence of growth factors. Signaling by ERBB2 homodimers mainly activates the RAS/RAF/MAPK signaling cascade, while PI3K/AKT signaling is not significantly affected (Pickl and Ries 2009).
Trastuzumab (Herceptin), a recombinant antibody clinically approved as an anti-cancer therapeutic for ERBB2-overexpressing cancers, preferentially binds to ERBB2 homodimers (Pickl and Ries 2009).
Accurate functional analysis of ERBB2 signaling may require 3D instead of 2D cell culture (Pickl and Ries 2009).
ERBB2 homodimerization leads to activation of ERBB2 signaling in the absence of growth factors. Signaling by ERBB2 homodimers mainly activates the RAS/RAF/MAPK signaling cascade, while PI3K/AKT signaling is not significantly affected (Pickl and Ries 2009).
Trastuzumab (Herceptin), a recombinant antibody clinically approved as an anti-cancer therapeutic for ERBB2-overexpressing cancers, preferentially binds to ERBB2 homodimers (Pickl and Ries 2009).
Accurate functional analysis of ERBB2 signaling may require 3D instead of 2D cell culture (Pickl and Ries 2009).
所含基因
7 个基因